Three major research organizations are racing to develop new Ebola vaccines as health officials grow concerned about potential outbreaks. IAVI (International AIDS Vaccine Initiative), Moderna, and the University of Oxford have each launched vaccine development programs targeting the virus.
The timing reflects legitimate public health anxiety. While current Ebola vaccines exist, including the rVSV-ZEBOV vaccine developed by Merck, scientists recognize that expanding the vaccine arsenal strengthens global preparedness. Different vaccine platforms can reach different populations and offer backup options if supply chains face disruption.
IAVI, a nonprofit focused on vaccine development for diseases affecting low-income countries, brings decades of experience working in regions where Ebola outbreaks occur. Moderna, known for its mRNA vaccine technology deployed during the COVID-19 pandemic, applies that same platform to Ebola. The University of Oxford contributes academic rigor and has a track record of rapid vaccine development from its work on COVID-19 and other diseases.
Each approach offers distinct advantages. mRNA vaccines, like Moderna's candidate, can be manufactured quickly and stored efficiently compared to some traditional platforms. Oxford's work builds on established vaccine development expertise. IAVI's involvement ensures that resulting vaccines address the specific needs of affected regions in Africa.
Ebola poses a genuine threat. The virus kills 25 to 90 percent of infected people depending on the strain. Between 2014 and 2016, West Africa experienced the largest Ebola outbreak on record, killing over 11,000 people. More recent smaller outbreaks in Central Africa have kept the virus on epidemiologists' radar.
Having multiple vaccines in development provides redundancy in the global health system. If one candidate faces manufacturing delays or proves less effective than hoped, others can fill the gap. This portfolio approach proved valuable during COVID-19 when no single vaccine could meet worldwide demand